FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:438-450 July 29, 2004 Number 5 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Pawlotsky, J.-M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Hepatitis C virus (HCV) infection is highly prevalent and is associated with substantial morbidity and mortality among persons infected with the human immunodeficiency virus (HIV). We compared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of chronic HCV infection in patients who were also infected with HIV.

Methods A total of 868 persons who were infected with both HIV and HCV and who had not previously been treated with interferon or ribavirin were randomly assigned to receive one of three regimens: peginterferon alfa-2a (180 µg per week) plus ribavirin (800 mg per day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plus ribavirin. Patients were treated for 48 weeks and followed for an additional 24 weeks. The primary end point was a sustained virologic response (defined as a serum HCV RNA level below 50 IU per milliliter at the end of follow-up, at week 72).

Results The overall rate of sustained virologic response was significantly higher among the recipients of peginterferon alfa-2a plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 percent, P<0.001), or peginterferon alfa-2a plus placebo (40 percent vs. 20 percent, P<0.001). Among patients infected with HCV genotype 1, the rates of sustained virologic response were 29 percent with peginterferon alfa-2a plus ribavirin, 14 percent with peginterferon alfa-2a plus placebo, and 7 percent with interferon alfa-2a plus ribavirin. The corresponding rates among patients infected with HCV genotype 2 or 3 were 62 percent, 36 percent, and 20 percent. Neutropenia and thrombocytopenia were more common among patients treated with regimens that contained peginterferon alfa-2a, and anemia was more common among patients treated with regimens containing ribavirin.

Conclusions Among patients infected with both HIV and HCV, the combination of peginterferon alfa-2a plus ribavirin was significantly more effective than either interferon alfa-2a plus ribavirin or peginterferon alfa-2a monotherapy.

Source Information

From the Department of Medicine, Division of Infectious Diseases, University of California, San Diego (F.J.T.); the Fundacion de Investigacion de Diego, Santurce, Puerto Rico (M.R.-T.); the University of Bonn, Bonn, Germany (J.K.R.); Virgen del Rocío University Hospital, Seville, Spain (E.L.); Unidad Virus de la Immunodeficiencia Humana, Hospital Universitario La Paz, Madrid (J.G.-G.); Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Vita–Salute University, Milan (A.L.); the Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy (G.C.); Alfred Hospital, Melbourne, Victoria, Australia (J.S.); Groupe Hospitalier de la Pitié –Salpêtrière, Paris (C.K.); the University of British Columbia, Vancouver, Canada (J.M.); Instituto de Infectologia Emilio Ribas, São Paulo (H.S.); Roche, Nutley, N.J. (S.P., J.D.P., F.D.); Roche, Basel, Switzerland (U.M.S.); and Mount Sinai School of Medicine, New York (D.T.D.).

Address reprint requests to Dr. Torriani at the University of California, San Diego, AntiViral Research Center, 150 W. Washington St., Suite 100, San Diego, CA 92103, or at ftorriani{at}ucsd.edu.

Full Text of this Article

Related Letters:

Peginterferon plus Ribavirin for Hepatitis C in HIV-Infected Patients
Taylor L. E., Rich J. D., Tashima K. T., Gholam P. M., Torriani F. J., Dieterich D. T., Chung R. T., Andersen J., Volberding P., the AIDS Clinical Trials Group A5071 Study Team
Extract | Full Text | PDF  
N Engl J Med 2004; 351:2340-2342, Nov 25, 2004. Correspondence

This article has been cited by other articles:

• Rotman, Y., Liang, T. J. (2009). Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes. J. Virol. 83: 7366-7374 [Full Text]  
• Pawlotsky, J.-M. (2009). Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therapeutic Advances in Gastroenterology 2: 205-219 [Abstract]  
• Berenguer, J., Gonzalez-Garcia, J., Lopez-Aldeguer, J., Von-Wichmann, M. A., Quereda, C., Hernando, A., Sanz, J., Tural, C., Ortega, E., Mallolas, J., Santos, I., Miralles, P., Montes, M. L., Bellon, J. M., Esteban, H., on behalf of the GESIDA HIV/HCV cohort, (2009). Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 63: 1256-1263 [Abstract] [Full Text]  
• Poordad, F., Landaverde, C. (2009). Review: Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients. Therapeutic Advances in Gastroenterology 2: 91-97 [Abstract]  
• Mira, J. A., Lopez-Cortes, L. F., Barreiro, P., Tural, C., Torres-Tortosa, M., de los Santos Gil, I., Martin-Rico, P., Rios-Villegas, M. J., Hernandez-Burruezo, J. J., Merino, D., Lopez-Ruz, M. A., Rivero, A., Munoz, L., Gonzalez-Serrano, M., Collado, A., Macias, J., Viciana, P., Soriano, V., Pineda, J. A. (2008). Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 62: 1365-1373 [Abstract] [Full Text]  
• Morello, J., Rodriguez-Novoa, S., Jimenez-Nacher, I., Soriano, V. (2008). Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother 62: 1174-1180 [Abstract] [Full Text]  
• Crespo, M., Mira, J. A., Pineda, J. A., Eynde, E. V. d., Rios-Villegas, M. J., Collado, A., Giron-Gonzalez, J. A., Lopez-Cortes, L. F., Gonzalez-Serrano, M., Rivero, A., Merino, D., Esteban, J. I. (2008). Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Chemother 62: 793-796 [Abstract] [Full Text]  
• Mendes-Correa, M C, Cavalheiro, N P, Mello, C, Barone, A A, Gianini, R J (2008). Genotypic distribution of hepatitis C among hepatitis C and HIV co-infected patients in Brazil. Int J STD AIDS 19: 595-599 [Abstract] [Full Text]  
• Aguilar Marucco, D., Gonzalez de Requena, D., Bonora, S., Tettoni, C., Bonasso, M., De Blasi, T., D'Avolio, A., Sciandra, M., Siccardi, M., Baietto, L., Trentini, L., Sinicco, A., Cariti, G., Di Perri, G. (2008). The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother 61: 919-924 [Abstract] [Full Text]  
• Coriat, R., Podevin, P. (2008). Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient. Int J STD AIDS 19: 208-210 [Abstract] [Full Text]  
• Pineda, J. A., Mira, J. A., Gil, I. d. l. S., Valera-Bestard, B., Rivero, A., Merino, D., Giron-Gonzalez, J. A., Rios-Villegas, M. J., Gonzalez-Serrano, M., Collado, A., Garcia-Garcia, J. A., Carrillo-Gomez, R., Lopez-Cortes, L. F., Gomez-Mateos, J. (2007). Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 60: 1347-1354 [Abstract] [Full Text]  
• Payan, C., Pivert, A., Morand, P., Fafi-Kremer, S., Carrat, F., Pol, S., Cacoub, P., Perronne, C., Lunel, F., the ANRS HC02 RIBAVIC study team, (2007). Rapid and early virological response to chronic hepatitis C treatment with IFN {alpha}2b or PEG-IFN {alpha}2b plus ribavirin in HIV/HCV co-infected patients. Gut 56: 1111-1116 [Abstract] [Full Text]  
• Koziel, M. J., Peters, M. G. (2007). Viral Hepatitis in HIV Infection. NEJM 356: 1445-1454 [Full Text]  
• Marucco, D. A., Veronese, L., de Requena, D. G., Bonora, S., Calcagno, A., Cavecchia, I., Sinicco, A., De Rosa, F. G., Cariti, G., Di Perri, G. (2007). Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. J Antimicrob Chemother 59: 565-568 [Abstract] [Full Text]  
• Ghosn, J, Deveau, C, Goujard, C, Garrigue, I, Saichi, N, Galimand, J, Nagy, Z, Rouzioux, C, Meyer, L, Chaix, M-L, for the French PRIMO Cohort Study Group (ANRS CO 0, (2006). Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection. Sex. Transm. Infect. 82: 458-460 [Abstract] [Full Text]  
• Sherman, M, Yoshida, E M, Deschenes, M, Krajden, M, Bain, V G, Peltekian, K, Anderson, F, Kaita, K, Simonyi, S, Balshaw, R, Lee, S S, the Canadian Pegasys Study Group, (2006). Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 55: 1631-1638 [Abstract] [Full Text]  
• Verma, S. (2006). HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?. J Antimicrob Chemother 58: 496-501 [Abstract] [Full Text]  
• Manns, M P, Wedemeyer, H, Cornberg, M (2006). Treating viral hepatitis C: efficacy, side effects, and complications.. Gut 55: 1350-1359 [Full Text]  
• Soriano, V., Barreiro, P., Nunez, M. (2006). Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 57: 815-818 [Abstract] [Full Text]  
• Ramanathan, S., Cheng, A., Mittan, A., Ebrahimi, R., Kearney, B. P. (2006). Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.. J Clin Pharmacol 46: 559-566 [Abstract] [Full Text]  
• Macias, J, Giron-Gonzalez, J A, Gonzalez-Serrano, M, Merino, D, Cano, P, Mira, J A, Arizcorreta-Yarza, A, Ruiz-Morales, J, Lomas-Cabeza, J M, Garcia-Garcia, J A, Corzo, J E, Pineda, J A (2006). Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 55: 409-414 [Abstract] [Full Text]  
• Hughes, C. A, Shafran, S. D (2006). Treatment of Hepatitis C in HIV-Coinfected Patients. The Annals of Pharmacotherapy 40: 479-489 [Abstract] [Full Text]  
• Wong, T., Lee, S. S. (2006). Hepatitis C: a review for primary care physicians. CMAJ 174: 649-659 [Abstract] [Full Text]  
• Klumpp, K., Leveque, V., Le Pogam, S., Ma, H., Jiang, W.-R., Kang, H., Granycome, C., Singer, M., Laxton, C., Hang, J. Q., Sarma, K., Smith, D. B., Heindl, D., Hobbs, C. J., Merrett, J. H., Symons, J., Cammack, N., Martin, J. A., Devos, R., Najera, I. (2006). The Novel Nucleoside Analog R1479 (4'-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture. J. Biol. Chem. 281: 3793-3799 [Abstract] [Full Text]  
• Pivert, A., Payan, C., Morand, P., Fafi-Kremer, S., Deshayes, J., Carrat, F., Pol, S., Cacoub, P., Perronne, C., Lunel, F. (2006). Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin. J. Clin. Microbiol. 44: 417-422 [Abstract] [Full Text]  
• McNelis, K. (2006). Management of Hepatitis C Infection in the HIV-Infected Patient. Journal of Pharmacy Practice 19: 37-52 [Abstract]  
• MAYOR, A. M., GOMEZ, M. A., FERNANDEZ, D. M., RIOS-OLIVARES, E., THOMAS, J. C., HUNTER, R. F. (2006). MORBIDITY AND MORTALITY PROFILE OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS WITH AND WITHOUT HEPATITIS C CO-INFECTION. Am J Trop Med Hyg 74: 239-245 [Abstract] [Full Text]  
• Brau, N. (2005). Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy. J Antimicrob Chemother 56: 991-995 [Abstract] [Full Text]  
• Rodriguez-Torres, M., Torriani, F. J., Soriano, V., Borucki, M. J., Lissen, E., Sulkowski, M., Dieterich, D., Wang, K., Gries, J.-M., Hoggard, P. G., Back, D., for the APRICOT Study Group, (2005). Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study. Antimicrob. Agents Chemother. 49: 3997-4008 [Abstract] [Full Text]  
• Mauss, S., Rockstroh, J. K. (2005). HCV/HIV-coinfection--is there a state of the art after APRICOT and RIBAVIC?. J Antimicrob Chemother 56: 615-618 [Abstract] [Full Text]  
• Koretz, R. L., Lipman, T. O. (2005). Update in Gastroenterology and Hepatology. ANN INTERN MED 143: 347-354 [Full Text]  
• Boston, N. S., Slish, J. C. (2005). Management of HIV Infection in Persons Co-infected With Hepatitis. Journal of Pharmacy Practice 18: 295-309 [Abstract]  
• Ballesteros, A. L., Fuster, D., Planas, R., Clotet, B., Tural, C. (2005). Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. J Antimicrob Chemother 55: 824-827 [Abstract] [Full Text]  
• Lo Re, V III, Kostman, J R (2005). Management of chronic hepatitis C. Postgrad. Med. J. 81: 376-382 [Abstract] [Full Text]  
• (2005). ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB. Evid. Based Med. 10: 3-3 [Full Text]  
• Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Morand, P., Goujard, C., Pialoux, G., Piroth, L., Salmon-Ceron, D., Degott, C., Cacoub, P., Perronne, C., for the ANRS HCO2 RIBAVIC Study Team, (2004). Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients: A Randomized Controlled Trial. JAMA 292: 2839-2848 [Abstract] [Full Text]  
• Manns, M. P., Wedemeyer, H. (2004). Treatment of Hepatitis C in HIV-Infected Patients: Significant Progress But Not the Final Step. JAMA 292: 2909-2913 [Full Text]  
• Taylor, L. E., Rich, J. D., Tashima, K. T., Gholam, P. M., Torriani, F. J., Dieterich, D. T., Chung, R. T., Andersen, J., Volberding, P., the AIDS Clinical Trials Group A5071 Study Team, (2004). Peginterferon plus Ribavirin for Hepatitis C in HIV-Infected Patients. NEJM 351: 2340-2342 [Full Text]  
• (2004). Rx for HCV-Coinfection: Pegylated Interferon + Ribavirin. AIDS Clin Care 2004: 1-1 [Full Text]  
• (2004). Pegylated Interferon Alfa-2a in Patients with HCV and HIV. JWatch Gastroenterology 2004: 5-5 [Full Text]  
• (2004). A Glimmer of Hope for HIV/HCV-Coinfected Patients. JWatch Infect. Diseases 2004: 3-3 [Full Text]